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TB in the United States: 
A Snapshot
Slow Progress Underscores Need for Expanded Approach
Preliminary 2017 data show current declines in U.S. TB cases are too slow to reach TB elimination in this century.
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The TB rate declined slightly (-2.5%) from 2016 to 2017 with approximately 2.8 cases per 100,000 persons.
A slight decrease in TB cases (-1.8%) was reported in 2017, decreasing from 9,256 in 2016 to 9,093 in 2017.
  The nation’s TB elimination goal is less than one case per 1 million people; however, there were 28 cases  
per 1 million people in 2017.
An expanded approach is needed to address two TB-related conditions – TB disease and latent TB infection.
TB Disease
TB bacteria become active if the immune  
system cannot stop them from growing. When  
TB bacteria are active (multiplying in the body), 
this is called TB disease. People with TB disease are 
sick and may also be able to spread the bacteria to 
other people. 
Latent TB infection
TB bacteria can live in the body without making 
a person sick. This is called latent TB infection. 
People with latent TB infection are not infectious 
and cannot spread TB bacteria to others. Latent 
TB infections can, however, progress to TB disease, 
which can be transmissible.
The TB Cycle
A Dual Approach to Eliminating TB
Resuming and accelerating progress toward TB elimination will require an intensified, dual approach that includes 
strengthening existing systems to prevent transmission of infectious TB disease and increasing efforts to detect and treat 
latent TB infection before it progresses to infectious TB.
Current TB control strategies prioritize the early diagnosis, isolation, and treatment of people with infectious TB disease.  
This approach protects patients’ health, prevents transmission to others, and allows for timely contact investigations to  
detect and prevent additional cases.
These TB control efforts are essential, but by themselves cannot eliminate the disease from the United States. More than  
80 percent of U.S. TB cases are associated with longstanding, untreated latent TB infections.
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Stopping TB Before the First Symptom:  
Tackling Latent TB Infection   
The Challenge
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Up t o 13 million people in the United States have latent  
TB infection, many of whom were born outside the  
United States and were infected many years earlier in 
areas of the world where TB is common.   
On a verage, 5 to 10 percent of people with latent TB 
infection will progress to infectious TB disease in their 
lifetime. However, this is much higher for some people.
T he vast majority of TB cases in the U.S. now are associated 
with these persons with longstanding, untreated latent TB 
infections which progress to active disease.
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80% of TB diagnoses in the U.S. associated 
with long-standing, latent TB infection
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R esuming progress toward TB elimination in the  
United States will require increased efforts to detect  
and treat latent TB infection. Public sector efforts alone 
will be insufficient to reach all of those who need to be 
tested and treated. Private providers and community 
health centers will play a key role in ensuring all those 
at risk are tested and offered treatment.
 Screening for latent TB should be targeted to individuals at high risk for TB disease, including:
People who were born or have lived in countries with high rates of TB
Because of the high exposure levels to TB in countries like Vietnam, the Philippines, China, India, Mexico, Guatemala, 
and Haiti, the prevalence of latent TB infection is much higher among individuals born in these nations.  
Studies indicate the majority of new TB cases in people born outside of the U.S. occurred at least 5 years after entry  
into the U.S.
O thers who are more likely to have had exposure to TB, including those who have lived in group settings where exposure 
is more likely 
Healthcar e workers and others who work in places at high risk for TB transmission
P eople at increased risk of progressing from latent TB infection to TB disease:
Currently, there is no test that can predict which people with latent TB infection will progress to TB disease, but certain 
risk factors increase the likelihood of activation, including:
             o  
             o  
             o  
             o  
HIV infection
Having been recently infected with TB bacteria (in the last 2 years)
Other health problems, like diabetes, that make it hard for the body to fight bacteria
Use of illegal drugs or abuse of alcohol
n  I ndividuals at risk of developing TB disease who are diagnosed with latent TB infection should be prioritized for treatment. 
Completing a treatment regimen for latent TB infection can reduce a person’s chance of developing TB disease by 90%.
CDC research has identified a simpler treatment regimen that can prevent the progression to TB disease in people who 
are diagnosed with latent TB infection. This FDA-approved regimen is 12 once-weekly doses of isoniazid and rifapentine, 
compared to other treatment regimens that include a 270-dose, nine-month daily regimen of isoniazid.
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Ending TB Transmission: Treating TB Disease
The Challenge
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Efforts to control TB are largely focused on quickly identifying and treating people with TB disease to cure the disease  
and prevent ongoing transmission. This work is led by CDC and health departments across the country.
These efforts have had a major impact, preventing as many as 300,000 cases over the last 20 years.
Enhanced control efforts will be needed to resume progress toward TB elimination. 
Priorities
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Strengthening health department TB control programs is essential to protect the health of individuals and communities.   
The latest national TB surveillance data, combined with information from recent outbreak investigations, confirm that 
preventing the transmission of infectious TB disease remains a challenge.
TB among people born in the United States, particularly children, is a key marker of recent transmission. After years of 
decline, TB rates have stopped declining among people born within the United States. In addition, more than one in 10 TB 
cases among persons born in the United States occurred among children (younger than 15).
TB control programs in state and local health departments need to maintain the ability to respond to every case of infectious 
TB disease. 
Combating Drug Resistance
Given the severity of this disease, it is essential to strengthen TB control systems and ensure that every active case of TB disease is 
effectively detected and treated. Treatments for TB disease can be difficult to complete, and failing to do so can result in TB bacteria 
becoming drug resistant. Treating drug resistant TB disease can be a complex, long, challenging, and expensive process. 
Multidrug-resistant TB (MDR TB) is resistant to at least two of the best and most important anti-TB drugs: isoniazid and 
rifampin. Extensively drug-resistant TB (XDR TB) is a rare type of MDR TB that is resistant to isoniazid and rifampin, as well as any 
fluoroquinolone and at least one of three injectable second-line drugs (i.e., amikacin, kanamycin, or capreomycin).
People undergoing treatment for MDR or XDR TB face the most devastating consequences. Treatment can take two or more years 
and the medicines are more expensive, less effective, and can often cause serious side effects. (See “The Costly Burden of Drug-
Resistant TB in the U.S.”)
The Path to Elimination
Eliminating TB, a debilitating and potentially life-threatening disease, would protect the health of Americans and reduce the 
burden on the health care system. Treatment for infectious TB disease typically requires at least 180 days of medicine, blood 
tests, and doctor visits. Treatment costs per case range from $18,000 up to $513,000 for extensively drug-resistant TB. In 
comparison, treatment for latent TB infection can take as little as 3 months and typically costs $600.
While public health efforts have been focused largely on the necessity of stopping transmission and curbing outbreaks, it is 
critical to also address the pool of individuals with latent TB infection at risk for developing infectious TB disease.
The end game of TB elimination requires engaging additional partners who can identify people at high risk for latent  
TB infection in their states and communities – and can test, diagnose, and treat them. Providers serving communities with  
high-risk populations, and leaders in these communities, are crucial to the successful expansion of testing and treatment 
initiatives for people with latent TB infection. 
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